Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 771

Sort by

Sort Order Select

Journal Articles

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

Vandana Chaturvedi, Nora Lakes, Minh Tran, Natalie Castillo, Michael B. Jordan

Blood (2021) 138 (12): 1034–1039.

https://doi.org/10.1182/blood.2020007930

Published: 2021

Journal Articles

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

Blood (2021) 137 (25): 3495–3506.

https://doi.org/10.1182/blood.2020007303

Published: 2021

Includes: Supplemental data

Journal Articles

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

Lauren K. Meyer, Katherine C. Verbist, Sabrin Albeituni, Brooks P. Scull, Rachel C. Bassett, Alexa N. Stroh, Heather Tillman, Carl E. Allen, Michelle L. Hermiston, Kim E. Nichols

Blood (2020) 136 (6): 657–668.

https://doi.org/10.1182/blood.2020006075

Published: 2020

Includes: Supplemental data

Journal Articles

Ruxolitinib for steroid-resistant acute GVHD

Antonio Maria Risitano, Regis Peffault de Latour

Blood (2020) 135 (20): 1721–1722.

https://doi.org/10.1182/blood.2020005364

Published: 2020

Journal Articles

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Madan Jagasia, Miguel-Angel Perales, Mark A. Schroeder, Haris Ali, Nirav N. Shah, Yi-Bin Chen, Salman Fazal, Fitzroy W. Dawkins, Michael C. Arbushites, Chuan Tian, Laura Connelly-Smith, Michael D. Howell, H. Jean Khoury

Blood (2020) 135 (20): 1739–1749.

https://doi.org/10.1182/blood.2020004823

Published: 2020

Includes: Supplemental data

Journal Articles

Verruconis gallopava in a patient with myelofibrosis on ruxolitinib

Andrew Hsu, Veronica Ulici

Blood (2020) 135 (14): 1189.

https://doi.org/10.1182/blood.2020004799

Published: 2020

Journal Articles

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Nicole Mollé, Spencer Krichevsky, Pouneh Kermani, Richard T. Silver, Ellen Ritchie, Joseph M. Scandura

Blood (2020) 135 (13): 1062–1066.

https://doi.org/10.1182/blood.2019003050

Published: 2020

Includes: Supplemental data

Journal Articles

Ruxolitinib: gaining more than intended

Graeme Greenfield, Mary Frances McMullin

Blood (2020) 135 (13): 983–984.

https://doi.org/10.1182/blood.2020005135

Published: 2020

Journal Articles

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

Jennifer M. O’Sullivan, Angela Hamblin, Christina Yap, Sonia Fox, Rebecca Boucher, Anesh Panchal, Samah Alimam, Helene Dreau, Kieran Howard, Pauline Ware, Nicholas C. P. Cross, Mary Frances McMullin, Claire N. Harrison, Adam J. Mead

Blood (2019) 134 (23): 2107–2111.

https://doi.org/10.1182/blood.2019001861

Published: 2019

Includes: Supplemental data

Journal Articles

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Blood (2019) 134 (21): 1832–1846.

https://doi.org/10.1182/blood.2019000162

Published: 2019

Includes: Supplemental data

Journal Articles

Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis

Tanya Burton, Kejal Parikh, Manish Patel, Kevin Sundquist, Lincy S. Lal, Ronda Copher, Aaron T. Gerds, MD MS

Blood (2019) 134 (Supplement_1): 4750.

https://doi.org/10.1182/blood-2019-124651

Published: 2019

Journal Articles

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Stephen E Kurtz, PhD, Christopher A. Eide, Andy Kaempf, MS, Nicola Long, Anupriya Agarwal, PhD, Cristina E. Tognon, Motomi Mori, PhD, Brian J. Druker, Jeffrey W. Tyner

Blood (2019) 134 (Supplement_1): 878.

https://doi.org/10.1182/blood-2019-126020

Published: 2019

Journal Articles

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Christian Hurtz, PhD, Gerald Wertheim, MD, PhD, Joseph Patrick Loftus, BS, Daniel Blumenthal, PhD, Anne Lehman, Yong Li, Bryan Manning, Katherine D Cummins, BMBS, Janis K Burkhardt, PhD, Alexander E. Perl, MD, Martin Carroll, MD, Sarah K. Tasian, MD

Blood (2019) 134 (Supplement_1): 747.

https://doi.org/10.1182/blood-2019-123514

Published: 2019

Journal Articles

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Blood (2019) 134 (Supplement_1): 839.

https://doi.org/10.1182/blood-2019-127488

Published: 2019

Journal Articles

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Blood (2019) 134 (Supplement_1): 807.

https://doi.org/10.1182/blood-2019-126773

Published: 2019

Journal Articles

Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Koji Sasaki, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naval G. Daver, MD, Koichi Takahashi, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Marina Y Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2019) 134 (Supplement_1): 1312.

https://doi.org/10.1182/blood-2019-131998

Published: 2019

Journal Articles

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Blood (2019) 134 (Supplement_1): 469.

https://doi.org/10.1182/blood-2019-123367

Published: 2019

Journal Articles

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Manjola Balliu, PhD, Laura Calabresi, PhD, Niccolò Bartalucci, PhDBSc, Laura Maggi, PhD, Francesco Annunziato, PhD, Paola Guglielmelli, MD PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 471.

https://doi.org/10.1182/blood-2019-123685

Published: 2019

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Haris Ali, MD, David Snyder, MD, Tracy Stiller, MS, Timothy Synold, PhD, Saloomeh Mokhtari, Joycelynne Palmer, PhD, Amandeep Salhotra, MD, Vinod A. Pullarkat, MD, Ji-lian Cai, MD, Stephen J Forman, MD, Matthew Mei, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

JAK inhibition for murine HLH requires complete blockade of IFN-γ signaling and is limited by toxicity of JAK2 inhibition

BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia

JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation

Ruxolitinib for steroid-resistant acute GVHD

Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial

Verruconis gallopava in a patient with myelofibrosis on ruxolitinib

Ruxolitinib can cause weight gain by blocking leptin signaling in the brain via JAK2/STAT3

Ruxolitinib: gaining more than intended

The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib

JAK2 -mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms

Real-World Analysis of Ruxolitinib Treatment Patterns and Outcomes Among Patients with Myelofibrosis

Patterns of Sensitivity Exhibited By Venetoclax-Inclusive Drug Combinations in Acute Myeloid Leukemia

Oncogene-Independent Adaptation of Pre-B Cell Receptor Signaling Confers Drug Resistance and Signaling Plasticity in Ph-like ALL

Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience

Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax

Outcomes of Patients with Acute Myeloid Leukemia (AML) with Myelodysplasia Related Changes (AML-MRC) Are Dependent on Diagnostic Criteria and Therapy

Single-Cell Analysis Based Dissection of Clonality in Myelofibrosis

Dysregulated IL-6/GP130/JAK Signaling in Calreticulin Mutated Myeloproliferative Neoplasms (MPN)

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only